LGD-3303

LGD-3303 is a nonsteroidal selective androgen receptor modulator (SARM) developed by Ligand Pharmaceuticals — the same program that produced LGD-4033. It binds the androgen receptor (AR) directly and drives tissue-selective activation: full agonism where you want it (muscle, bone) and partial agonism where you don't (prostate). Mechanistically it's closer to a "designed" anabolic than a steroid — no aromatization, no 5α-reductase substrate activity, and selectivity driven by receptor conformation rather than tissue distribution.

Full Agonism at Muscle AR, Partial Agonism at Prostate#

The headline mechanism is the dissociation between anabolic (muscle) and androgenic (prostate) AR activation. In castrated rat models, LGD-3303 fully restored levator ani mass — matching testosterone's effect — while failing to meaningfully stimulate ventral prostate growth even at supratherapeutic plasma levels.

"LGD-3303 was a full agonist in muscle but only a partial agonist in prostate and did not stimulate ventral prostate growth above intact-control levels even at high plasma concentrations." — Vajda EG et al., Journal of Pharmacology and Experimental Therapeutics, 2009

The key point buried in the pharmacology: prostate tissue concentrations of LGD-3303 actually exceed muscle concentrations. Selectivity is therefore not a distribution trick — it comes from altered AR conformation and differential cofactor recruitment at the receptor. LGD-3303 folds the AR in a way that recruits coactivators in myocyte nuclei but fails to assemble the full transcriptional complex in prostate epithelium. Practical upshot: you get muscle-building AR signaling without the prostate hypertrophy that dose-limits testosterone.

Downstream Anabolic Transcription in Muscle#

Once AR is activated in skeletal muscle, the same canonical anabolic program runs as with testosterone: upregulation of MyoD and myogenin, increased local IGF-1 signaling, enhanced protein synthesis, and suppression of myostatin output. Because AR activation in muscle is full, users running 15–20 mg/day report strength gains that punch above what a "mild SARM" label would suggest — one community comparison put split-dose 3303 ahead of 100 mg/week anavar on strength, which is credible for a full AR agonist in myocytes.

This is also why 3303 reads as "dry" rather than "wet" in community logs. There's no aromatization to estradiol, so extracellular water retention and subcutaneous bloat are minimal — you get the AR-driven myofibrillar growth without the estrogenic volumization that makes LGD-4033 feel puffy.

"LGD-3303 is way drier than LGD-4033 — I noticed harder, leaner muscles and less water retention even at a similar dose." — r/SARMs community report, 2024

Bone and Connective Tissue Effects#

The original Ligand program targeted osteoporosis, and the bone data is the strongest non-muscle mechanism on file. In osteopenic rats, LGD-3303 restored bone mineral density and increased cortical bone thickness, and stacked additively on top of alendronate.

"LGD-3303 increased BMD and cortical bone thickness, and when combined with alendronate produced additive effects on bone mass restoration in osteopenic rats." — Vajda EG et al., Journal of Bone and Mineral Research, 2009

For the physique-focused reader, this matters for two reasons. First, osteoblast AR activation plus the anti-estrogenic environment created by stacking means connective tissue and joint response tends to hold up well on 3303 runs — lifters pushing loads don't get the "stronger than my tendons" mismatch that pure mass-builders produce. Second, for older users running light AAS-sparing protocols, the bone-density angle is a genuine secondary benefit with animal evidence behind it, even if human data is absent.

HPG Axis Suppression#

Full AR agonism at the hypothalamus and pituitary means LGD-3303 provides the same negative feedback signal as testosterone, regardless of what vendor pages originally claimed about "non-suppressive" SARMs. GnRH pulses dampen, LH and FSH drop, and endogenous testosterone production follows. By week 4–6 at 15–20 mg/day, most users are meaningfully suppressed on bloodwork, which is why PCT is non-negotiable beyond a short run and why stacking with a TRT dose of testosterone is standard for longer or higher-dose protocols.

The practical implication: plan the exit before initiating the cycle. Nolvadex-based PCT (20/20/10/10) recovers most users from an 8-week run; bloodwork at week 2 and week 6 post-cycle confirms LH/FSH and total test have returned.

No Aromatization, No 5α-Reductase Conversion#

LGD-3303 is not a steroid — it's a pyrroloquinolinone. It isn't a substrate for aromatase (no estradiol conversion, no gyno risk, no estrogenic water retention) and isn't a substrate for 5α-reductase (no scalp DHT metabolism). For hair-sensitive users this is a partial win: the DHT-amplification pathway that makes testosterone aggressive on genetically predisposed follicles simply doesn't apply.

However — and this is where users get caught — the scalp follicle still has androgen receptors, and LGD-3303 is a full AR agonist. It signals directly at the follicle without needing DHT as an intermediate. So finasteride or dutasteride offer no protection here (there's nothing for them to inhibit). The rational hair-retention move on a 3303 cycle is a topical AR antagonist — RU58841 or pyrilutamide — which blocks the receptor locally at the scalp without interfering with the anabolic signaling you want in muscle. Topical finasteride is a weaker but cheaper hedge for the minority of DHT conversion that does happen systemically.

Pharmacokinetic Reality: The Short Half-Life#

The final mechanism-adjacent point the reader needs to internalize: LGD-3303's half-life is roughly 6–8 hours, not 24–36 hours like its cousin LGD-4033. That means AR occupancy rises and falls through the day on single-dose protocols, which produces uneven signaling and leaves anabolic windows dark. Splitting the daily dose 2–3× — AM, midday, and pre-workout is a clean template — keeps plasma levels (and AR occupancy) in a useful range throughout the day. This is the single most common dosing mistake in 3303 logs, and fixing it usually explains why a "re-run" feels materially stronger than the first attempt.

Common (most users)#

• HPG suppression — by week 4–6 at 15–20 mg/day, LH/FSH drop and total test follows. Not a "non-suppressive" compound despite old marketing. Mitigation: plan PCT (nolva 20/20/10/10 or nolva+clomid) for any run past 4 weeks, and don't skip post-cycle bloodwork at week 2 and week 6.
• HDL drop — expect a 15–30% decline over 8 weeks, typical of the SARM class. Mitigation: citrus bergamot 1000 mg/day, fish oil 3–4 g/day EPA+DHA, and keep saturated fat in check. Sister-compound data shows reversibility post-cycle.

"Reversible dose-dependent reductions in HDL cholesterol and mild increases in liver enzymes were observed in human subjects taking LGD-4033." — Basaria et al., J Gerontol A Biol Sci Med Sci (2013)

• Blood pressure creep — one of the more consistent complaints on 3303. Mitigation: cuff readings weekly, telmisartan 20–40 mg or Carditone if you're trending over 135/85. Cut stimulants and high-sodium junk on cycle.
• Mild lethargy / headaches — usually a downstream BP symptom or suppression-related. Mitigation: address BP first, check hydration, and if it persists past week 2 pull the dose back 5 mg.
• Libido dip late cycle — shows up as natural test suppresses. Mitigation: low-dose tadalafil 2.5–5 mg daily smooths it, and a clean PCT restores function.

Uncommon (dose-dependent or individual)#

• Transaminase elevation — mild ALT/AST bumps are documented with sister compounds; more likely at 25–30 mg/day or when stacked with another oral. Back off if ALT crosses ~2× ULN on mid-cycle labs, and don't pair with anavar, winstrol, or epistane.
• Androgenic hair shedding — LGD-3303 doesn't convert to DHT, but it's a full AR agonist and signals directly at the follicle. Mitigation: hair-sensitive users add topical RU58841 or pyrilutamide, or run topical finasteride. Oral finasteride won't help here — the pathway isn't 5-AR.
• Acne / oily skin — less common than with wet AAS but possible. Mitigation: standard skincare (adapalene, benzoyl peroxide), and if it escalates reduce the dose.
• Aggression / irritability — AR full agonism in the CNS, dose-related. Back off 5 mg if it's affecting sleep or relationships.
• Strength outpacing connective tissue — 3303 hits AR hard enough that tendons lag. Mitigation: conservative load progression weeks 1–3, and 250 mg/day MK-677 or a BPC-157 run in parallel if you're pushing PRs.

Rare but serious#

• Clinically significant hypertension — stage 2 BP (>140/90 sustained) with headaches or visual changes. Stop the cycle, address BP medically, don't wait it out.
• Marked lipid dysregulation — HDL crashing below 25 mg/dL or LDL climbing sharply. Pull the compound; these resolve post-cycle but chronic exposure is not a smart bet.
• Hepatic stress — ALT/AST above 3× ULN, RUQ pain, dark urine, jaundice. Stop immediately and get labs.
• Prolonged post-cycle suppression — LH/FSH and test still suppressed at week 8+ post. Extend PCT, add enclomiphene, and get a full endocrine panel if it drags past 12 weeks.

"LGD-3303 was a full agonist in muscle but only a partial agonist in prostate and did not stimulate ventral prostate growth above intact-control levels even at high plasma concentrations." — Vajda et al., JPET (2009)

The prostate selectivity is a genuine advantage of this molecule — BPH symptoms and prostate growth are not the concern here that they are with exogenous testosterone.

Hard contraindications#

• Untreated hypertension. BP control first, cycle second. Non-negotiable.
• Pre-existing dyslipidemia (familial hypercholesterolemia, low HDL at baseline, active statin-managed cardiovascular disease).
• Hepatic impairment — any active liver pathology or elevated baseline LFTs.
• Pregnancy, lactation, or plans for near-term conception. No data, full AR agonist in muscle, HPG-suppressive.
• Tested athletes. LGD-3303 and its metabolites are WADA-prohibited and readily detectable in urine for weeks.

"Several major metabolites of LGD-3303 were detected in equine urine samples after administration, supporting the compound's detectability for anti-doping purposes." — Wong et al., Drug Testing and Analysis (2023)

• Stacking with other hepatotoxic orals (anavar, winstrol, superdrol, epistane) — additive liver and lipid hit is not worth the marginal gain.

Women and PCT considerations#

There is no human data on LGD-3303 in women, and as a full AR agonist in muscle tissue it carries virilization risk (voice deepening, clitoral hypertrophy, androgenic hair pattern shifts) that may not be fully reversible. Women pursuing SARM-based recomp generally stick with low-dose ostarine (5–10 mg) instead.

For men, PCT is required on any run past 4 weeks. Standard protocol is nolvadex 20/20/10/10 or a nolva (20 mg) + clomid (25 mg) combo for 4 weeks, starting the day after your last dose given the short half-life. Run bloodwork at post-cycle week 2 and week 6 to confirm LH, FSH, and total test are recovering. If recovery stalls past 8–12 weeks post, enclomiphene 12.5 mg daily is the next tool. Keep cycles to 8–10 weeks maximum — "SARMs are mild, I'll run 12" is where the serious lipid and BP damage accumulates.